v3.25.2

Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2025	Dec. 31, 2024
Current assets
Cash	$ 3,125,101	$ 4,091,990
Acquired patents, net		1,779
Total assets	3,125,101	4,093,769
Current liabilities
Accounts payable & accrued interest	1,296,476	1,177,536
Deferred compensation – related party		306,281
Total current liabilities	1,685,609	1,559,733
Total liabilities	1,685,609	1,559,733
Stockholders’ equity
Common stock, $0.001 par value; 100,000,000 shares authorized; 13,472,939 and 13,152,729 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	13,473	13,153
Additional paid-in capital	74,863,037	68,674,261
Accumulated deficit	(73,437,018)	(66,153,378)
Total stockholders’ equity	1,439,492	2,534,036
Total liabilities and stockholders’ equity	3,125,101	4,093,769
Related Party [Member]
Current liabilities
Deferred compensation – related party	306,281	306,281
Unreimbursed expenses – related party	$ 82,852	$ 75,916

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Greenwich LifeSciences, Inc. 10-Q